By Heather Landi
The Department of Veterans Affairs will push off deployment of a new electronic medical records system to additional medical facilities until 2023 to address outages that have plagued the software at current sites.
read more
By Angus Liu
After a report of a potential Seagen acquisition by Merck emerged, industry watchers have been busy assessing whether a deal would indeed help Merck reduce its dependence on Keytruda and boost return for investors. While Seagen investors liked a $215-per-share price assumed by SVB Securities, Merck shareholders have some doubts.
read more
By Andrea Park
Medtronic’s line of devices to strengthen the spine just got a bit stronger itself.
read more
By Paige Minemyer
Optum is launching a new health plan solution that aims to reduce unnecessary testing and ensure that patients are receiving the screenings that are best for them.
read more
By Nick Paul Taylor
One year after Intellia’s landmark data, Novartis is making a play for the in vivo gene editing market. The move sees the Swiss pharma pay Precision BioSciences $75 million upfront, with up to $1.4 billion in milestones, to secure rights to a potential treatment for sickle cell disease and beta thalassemia.
read more
By Zoey Becker
As the industry sees more biosimilar uptake, Amgen says it's well prepared. Last week, the company presented a preview of its annual trends in biosimilars report at the BIO 2022 convention in San Diego. Next year, Amgen is planning to really make its mark with the industry's first US biosimilar of AbbVie's Humira.
read more
By Andrea Park
As ventilators and other respiratory devices became more crucial than ever throughout the COVID-19 pandemic, so too did any safety issues embedded in the machines become more apparent.
read more
By Fraiser Kansteiner
After Russia’s war in Ukraine escalated sharply in February, Pfizer swiftly pledged to donate the sum of its Russian profits, declaring the cash would help causes that provide direct support to the people of Ukraine. Three months later, the company says it’s making good on that promise.
read more
By Gabrielle Masson
Gene editing giant CRISPR Therapeutics is moving away from multiple myeloma candidate CTX120, while a small, separate dataset released yesterday sent the company’s stock plummeting.
read more
By Conor Hale
Cleared for use in Europe, GE Healthcare aims to make it easier for clinicians to keep track of patients vital signs without performing routine check-ins.
read more
By Sharon Klahr Coey
It turns out that even more than the blinding pain, the nausea, the photosensitivity or crushing fatigue, the worst part of migraine is often the stigma attached to it. Those results are part of Eli Lilly’s fourth OVERCOME migraine data study.
read more
By Robert King
CMS is proposing an $810 million cut to Medicare payments to home health agencies in 2023 due in part to a change to how the agency calculates payments.
read more
By Natalie Missakian
Patient groups may view pharma more favorably thanks to its work during the pandemic, but HIV and AIDS patients groups are a tougher sell, according to a new survey.
read more
